Sustained Effectiveness of Lanadelumab in Preventing Hereditary Angioedema Attacks: The ENABLE Study
Open Access
- 6 August 2026
- journal article
- research article
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (8) , e70190
Abstract
Background: Lanadelumab has been approved for hereditary angioedema (HAE) long‐term prophylaxis since 2018. The Phase 4, prospective ENABLE Study (NCT04130191) evaluated the long‐term effectiveness and safety of lanadelumab in clinical practice across Europe and the Middle East. Methods: Patients with HAE aged ≥ 12 years initiating lanadelumab treatment (300 mg every 2 weeks) per approved product labeling were recruited from Austria, Germany, Israel, Italy, Kuwait, Spain, and Switzerland and followed for up to 36 months (± 30 days). The primary objective was to evaluate lanadelumab effectiveness for HAE attack prevention. Safety and patient‐reported health‐related quality of life (HRQoL) were also evaluated. Results: Outcomes were analyzed in 138 patients (mean [range] age: 41.0 [14–79] years; 62.3% female; 92.0% HAE‐C1INH‐Type1), of whom > 60% extended dosing intervals by Month 12. Over a mean ± SD treatment duration of 28.6 ± 9.8 months, mean ± SD patient‐reported HAE attack rate decreased from 3.88 ± 3.43 attacks/month pre‐lanadelumab to 0.30 ± 0.53 attacks/month (mean decrease, 84% [median 96%]). The incidence‐rate ratio was 0.07 (95% CI: 0.06–0.10), reflecting a 93% reduction from modeled pre‐lanadelumab rates. Overall, 95/138 patients reported treatment‐emergent adverse events (TEAEs); most were unrelated to lanadelumab (82.3%). Of the 17.7% of TEAEs considered treatment‐related, injection‐site reactions, headache, fatigue, and asthenia occurred in > 1 patient. Before lanadelumab initiation, most patients reported moderate‐to‐large HRQoL impairments; clinically meaningful improvements were observed 1 month after lanadelumab initiation and sustained throughout the study. Conclusions: Real‐world data from ENABLE demonstrated long‐term effectiveness of lanadelumab in patients with HAE aged ≥ 12 years and a safety profile consistent with previous clinical studies.Keywords
This publication has 36 references indexed in Scilit:
- A national survey of four decades of hereditary angioedema prophylaxis: Efficacy and safety of old and new drugsClinical Immunology, 2025
- Uncovering the true burden of hereditary angioedema due to C1-inhibitor deficiency: A focus on the Asia-Pacific regionJournal of Allergy and Clinical Immunology, 2023
- Hereditary angioedema in older adultsAnnals of Allergy, Asthma & Immunology, 2023
- Sensitivity to change and minimal clinically important difference of the angioedema control testClinical and Translational Allergy, 2023
- Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedemaAnnals of Allergy, Asthma & Immunology, 2023
- Validation of the Angioedema Control Test (AECT)—A Patient-Reported Outcome Instrument for Assessing Angioedema ControlThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Patient-reported burden of hereditary angioedema: findings from a patient survey in the United StatesAnnals of Allergy, Asthma & Immunology, 2020
- Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema AttacksJAMA, 2018
- Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiencyJournal of Allergy and Clinical Immunology, 2012
- The Fatigue Severity ScaleArchives of Neurology, 1989